Addressing long-term PPI safety

The advent of antisecretory drugs, such H2-receptor antagonists (H2RAs) and proton pump inhibitors (PPIs), has revolutionized the management of acid-related diseases, leading to the virtual abolition of elective surgery for ulcer disease and relegating anti-reflux surgery to patients with reflux disease not adequately managed by medical therapy. PPIs remain the mainstay of medical treatment for gastro-esophageal reflux disease (GERD) [1 –3]. They act indirectly by reducing the amount and concentration of gastric secretion available for reflux, thus lessening the aggressive power of the refluxed material [4].
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Tags: Commentary Source Type: research